Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions – III

Kerridge, Bradley T.; Saha, Tulshi D.; Chou, S. Patricia; Zhang, Haitao; Jung, Jeesun; Ruan, W. June; Smith, Sharon; Huang, Boji; Hasin, Deborah S.

doi:10.1016/j.drugalcdep.2015.08.026

Cited by 82 publications

(69 citation statements)

References 72 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given sex and racial/ethnic differences in patterns of NMPO use and disorder (Back et al, 2010; Kerridge et al, 2015; Salas et al, 2016; SAMHSA, 2015b), future work should implement APC analyses by sex and race/ethnicity.…”

Section: Discussionmentioning

confidence: 99%

“…Many states implemented legislation to control medical prescription of opioids (Franklin et al, 2015; Johnson, 2014). Several reports have described patterns of use (Kerridge et al, 2015; Martins et al, 2014), risk factors for use (Katz et al, 2013), or trends in NMPO use and disorder prevalence among adolescents and adults (Han et al, 2015; Jones, 2017; Martins et al, 2017; McCabe et al, 2014). From 2003 to 2014, overall prevalence of NMPO use decreased, while prevalence of frequent use and disorder increased (Han et al, 2015; Jones, 2017).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Age-related patterns in nonmedical prescription opioid use and disorder in the US population at ages 12-34 from 2002 to 2014*

Griesler²,

Wall

et al. 2017

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Objectives To estimate age-related patterns in nonmedical prescription opioid (NMPO) use in the US population and disorder among past-year users at ages 12–34 between 2002–2014, controlling for period and birth-cohort effects. Methods Data are from 13 consecutive cross-sectional National Surveys on Drug Use and Health (N = 542,556). Synthetic longitudinal cohorts spanning ages 12–34 were created and an age-period-cohort analysis was implemented based on the Intrinsic Estimator algorithm. Results In every birth cohort, past-year NMPO use increases during adolescence, peaks at ages 18–21, decreases through ages 30–34; disorder among past-year users increases from ages 18–21 through 30–34. Use at ages 12–34 decreased from the 1984–87 birth cohorts to more recently-born cohorts. Peak prevalence of use at ages 18–21 has also decreased, and the rates of increase from ages 14–17 to ages 18–21 are slowing down. Disorder at ages 18–34 increased from the 1976–79 to 1992–95 cohorts, but decreased at ages 12–17 from the 1992–95 to the most recently-born 2000–02 cohorts. The years 2010–2014 were characterized by lower NMPO use but higher disorder than 2002–2009. Conclusions Increasing NMPO disorder among users aged 18–34 warrants concern. However, declining NMPO use among 12–34 year-olds, a declining rate of increase from adolescence to early adulthood, and a suggestive decline in disorder among the most recent adolescent cohorts may forecast a potential reduction in the public health crisis associated with NMPO drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Age-related patterns in nonmedical prescription opioid use and disorder in the US population at ages 12-34 from 2002 to 2014*

Griesler²,

Wall

et al. 2017

Drug and Alcohol Dependence

View full text Add to dashboard Cite

show abstract

“…[15,28,30] Available data suggest that men are more likely than women to abuse prescription opioid analgesics. [31,[67][68][69] Men also appear to be more likely than women to abuse prescription opioid analgesics via non-oral routes (e.g., snorting or injection) (Figure 4). [28,67,70] Other clinically relevant gender differences in patterns of abuse have also been noted.…”

Section: Differences In Routes Of Abuse Between Populationsmentioning

confidence: 99%

Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations

Gąsior

Bond

Malamut

2015

Postgraduate Medicine

View full text Add to dashboard Cite

Prescription opioid analgesics are an important treatment option for patients with chronic pain; however, misuse, abuse and diversion of these medications are a major global public health concern. Prescription opioid analgesics can be abused via intended and non-intended routes of administration, both intact or after manipulation of the original formulation to alter the drug-delivery characteristics. Available data indicate that ingestion (with or without manipulation of the prescribed formulation) is the most prevalent route of abuse, followed by inhalation (snorting, smoking and vaping) and injection. However, reported routes of abuse vary considerably between different formulations. A number of factors have been identified that appear to be associated with non-oral routes of abuse, including a longer duration of abuse, younger age, male sex and a rural or socially deprived location. The development of abuse-deterrent formulations of prescription opioid analgesics is an important step toward reducing abuse of these medications. Available abuse-deterrent formulations aim to hinder extraction of the active ingredient, prevent administration through alternative routes and/or make abuse of the manipulated product less attractive, less rewarding or even aversive. There are currently five opioid analgesics with a Food and Drug Administration abuse-deterrent label, and a number of other products are under review. A growing body of evidence suggests that introduction of abuse-deterrent opioid analgesics in the USA has been associated with decreased rates of abuse of these formulations. The availability of abuse-deterrent formulations therefore appears to represent an important step toward curbing the epidemic of abuse of prescription opioid analgesics, while ensuring the availability of effective pain medications for patients with legitimate medical need.

show abstract

“…Unfortunately, only one large, epidemiological study to date has examined the association between PTSD diagnosis with NMOU and Opioid Use Disorder diagnosis. Utilizing NESARC-III, Kerridge et al (2015) found that a past year PTSD diagnosis was associated with higher odds of a past-year NMOU among both men and women, while a past year PTSD diagnosis was associated with higher odds of an Opioid Use Disorder diagnosis among women only, even after adjusting for covariates (i.e., sociodemographic factors, other psychiatric disorders) However, to date, no large, epidemiological studies have examined associations PTSD symptom clusters with NMOU and/or Opioid Use Disorder diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Past year non-medical opioid use and abuse and PTSD diagnosis: Interactions with sex and associations with symptom clusters

Smith

Cercone

et al. 2016

Addictive Behaviors

View full text Add to dashboard Cite

Introduction Few studies have examined the associations between posttraumatic stress disorder (PTSD) and non-medical opioid use (NMOU), particularly in general U.S. samples. Methods We analyzed data from wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), a nationally representative sample of non-institutionalized adults, to examine (1) the relationship between PTSD diagnosis with NMOU, Opioid Use Disorder diagnosis, and average monthly frequency of NMOU; and (2) the relationship between PTSD symptom clusters with NMOU, Opioid Use Disorder diagnosis, and average monthly frequency of NMOU. We also explored sex differences among these associations. Results In the adjusted model, a past year PTSD diagnosis was associated with higher odds of past year NMOU for women and men, but the association was stronger for women. In addition, a PTSD was associated with higher odds of an Opioid Use Disorder diagnosis for women, but not for men. With regards to the relationship between specific symptom clusters among those with a past year PTSD diagnosis, important sex differences emerged. For women, the avoidance symptom cluster was associated with higher odds of NMOU, an Opioid Use Disorder diagnosis, and average monthly frequency of NMOU, while for men the arousal/reactivity cluster was associated with higher odds of NMOU, an Opioid Use Disorder diagnosis, and average monthly frequency of NMOU. In addition, for men, the avoidance symptom cluster was associated with higher odds of an Opioid Use Disorder diagnosis, but a lower rate of average monthly frequency of NMOU. Conclusions Results add to the literature showing an association between PTSD and NMOU and suggest that PTSD is more strongly associated with substance use for women than men. Further, results based on individual symptom clusters suggest that men and women with PTSD may be motivated to use substances for different reasons.

show abstract

Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions – III

Cited by 82 publications

References 72 publications

Age-related patterns in nonmedical prescription opioid use and disorder in the US population at ages 12-34 from 2002 to 2014*

Age-related patterns in nonmedical prescription opioid use and disorder in the US population at ages 12-34 from 2002 to 2014*

Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations

Past year non-medical opioid use and abuse and PTSD diagnosis: Interactions with sex and associations with symptom clusters

Contact Info

Product

Resources

About